1. 所有文章
  2. Events
  3. Press Releases
  4. Publications

The radiosynthesis of [18F]fluoroacetate by a Tracerlab MX synthesizer in Shin-Kong Memorial Hospital.

1Chi-Wei Chang, 2Wen-Sheng Huang, 3Tsung-Hsun Yu, 5Ching-Huang Lo, 3,4Skye Hsin-Hsien Yeh* 1 R&D department, Primo Biotechnology Co., Ltd., Taipei, Taiwan 2 Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan 3 School of Medicine, National Defense Medical Center, Taipei, Taiwan 4 Brain Research Center, National Yang Ming Chaio Tung University, Taipei, Taiwan5…

Does 18F-PSMA-1007 PET/CT Effectively Detect Among Patients with Suspected Prostate Cancer-Case Report

Min-Che Tung1, Neng-Chuan Tseng2, Chao-Yu Hsu1, Wei-Chun Weng1, Henry Li-Hua Huang1, Yi-Sheng Lin1, Ya-Ting Huang3, Yen-Chuan Ou1,4 1Division of Urology, Department of Surgery, Tungs’ Taichung Metro Harbor Hospital, Taichung, Taiwan 2Division of Nuclear Medicine, Tungs’ Taichung Metro Harbor Hospital, Taichung, Taiwan 3Primo Biotechnology Co., Ltd, Taipei, Taiwan 4Department of Research, Tungs’ Taichung Metro Harbor Hospital,…

The evaluation in the efficacy of Radium-223 for overall survival among patients with mCRPC: A meta-analysis

Yen-Hsiang Chang1, Hao-Lun Luo2, Li-Yu Chen3, Shiang-Ling Lin3, Ya-Ting Huang3 1Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan 2Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan 3Primo Biotechnology Co., Ltd, Taipei, Taiwan This meta-analysis was presented at the 2024 Annual Meeting of the Taiwan Urological Association(2024 TUA). Radium-223 is the first FDA-approved…

Application of Radelumin(PSMA-1007) combined with MRS(Magnetic resonance spectroscopy) in assessment of benign and malignant prostate cancer.

Chih-Yi Wu1, Yu-Ming Fan2,3(co-first author), Chun-Hou Liao3,4, Ya-Ting Huang1,5, Ya-Yao Huang1,6, Jia-Hsin Fang2 1Primo Biotechnology Co., Ltd 2Department of Nuclear Medicine of Cardinal Tien Hospital 3School of Medicine, College of Medicine, Fu Jen Catholic University 4Department of Urology of Cardinal Tien Hospital 5Department of Medical Education and Research, Camillian Saint Mary’s Hospital 6Institute of Medical…

Primo wins 2023 TAIPEI Prominent Enterprise Award

We are greatly honored to receive the award of Investment Paradigm from Taipei City Government. Thanks to the Project of Subsidies & Incentives For Taipei Industry, Primo Biotechnology is able to grow faster and take on difficult challenges. About Primo Biotechnology Primo Biotechnology is a pioneering leader in Asia’s nuclear medicine sector, dedicated to the…

The Application of Detecting the Heterogeneity of Estrogen Receptor By 18F-fluoroestradiol PET/CT: A Systematic Review

Li-Yu Chen, Shiang-ling Lin, Ya-Yao Huang, Ya-Ting Huang Published by the 2023 Annual Conference of SNM, Taiwan Background 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) is a new convenient way to screen and analyze metastatic breast cancer (MBC) patients with uncertain estrogen receptor (ER), which the heterogeneity expression has long been a problem in figuring…

The Economic Evaluation of Diagnostic Tool with 18F-Fluorodeoxyglucose from Clinical Practice: A Systematic Review and Network Meta-analysis

Ya-Ting Huang, Yu-Ming Fan, Li-Yu Chen, Shiang-ling Lin, Chih-Yi Wu, Guang-Uei Hung, Ya-Yao Huang Published by the 2023 Annual Conference of SNM, Taiwan Background Imaging with 18F-fluorodeoxyglucose (FDG) plays a significant diagnostic role in cancer and non-cancer followed by influencing treatment decision-making. Because of the clinical benefits of FDG imaging, its cost-effectiveness is of interest….

The Application of 18F-FES PET in Clinical Cancer Care: A Systematic Review

Ya-Ting Huang, PhD , RN, NP,* Tom Wei-Wu Chen, MD, PhD , Li-Yu Chen, MS , Ya-Yao Huang, PhD , and Yen-Shen Lu, MD, PhD Published by Clinical Nuclear Medicine 48(2):p 132-142, February 2023 Abstract Background: [C-11] Pittsburgh Compound-B (PiB) is now almost routinely used to perform clinical studies for patients in the neurological department…

Primo Biotechnology Raises Over 6.5 Million USD in Funding, Pioneering an International-level Radiopharmaceutical Manufacturing Facility

Aiming at the Future of Precision Medicine Market Primo Biotechnology recently completed its seed round of funding, led by AVA Angels. The seed round successfully raised 4 million, combined with 2.5 million from the angel round, resulting in a total capital increase of 6.5 million for Primo Biotechnology within just two years of its establishment….

Comparing the Detection Performance Between mpMRI and PSMA-PET/CT in Patients with Localized Prostate Cancer: A Systematic Review and Meta-analysis

Yuh-Feng Wang, MD, PhD, Jyun-You Luo, MD, Li-Yu Chen, MS, Chi-Wei Chang, PhD, Ya-Ting Huang, RN, NP, PhD, Ya-Yao Huang, PhD, Yi-Hsiu Huang, MD, PhD Published by Clinical Nuclear Medicine 48(7):p e321-e331, July 2023. Abstract Purpose Multiparametric MRI (mpMRI) has been promoted as an auxiliary diagnostic tool for prostate biopsy. However, prostate-specific membrane antigen (PSMA)…

Compare the Effective dose and convenience of clinical work between the 99mTc-ECD brain perfusion SPECT and 18F FDG brain scan

Chia-Yi Huang , Yu-Min Fan , Chih-Yi Wu Purpose 99mTc ECD brain perfusion SPECT is routine used for neurological cognitive disorders and epilepsy with scintillation camera. 18F-FDG is widely used in neurological examinations, and human brain research. This study was to clarify the advantages and disadvantages of 99mTc-ECD and 18F-FDG for brain scan.

Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers: A Systemic review and Meta-analysis

Wen-Yi Chang, PhD, Neng-Chuan Tseng, MD, Li-Yu Chen, MN, Chi-Wei Chang, PhD, Ya-Yao Huang, PhD, Ya-Ting Huang, PhD, Yen-Chuan Ou, MD, Nan-Jing Peng, MD, PhD Published by Clinical Nuclear Medicine 48(2):p 132-142, February 2023. Abstract Purpose 18F-FDG is the dominant radiotracer in oncology; however, it has limitations. Novel labeled fibroblast activation protein (FAP) radiotracers have…